Watts, Colin, Ashkan, Keyoumars, Jenkinson, Michael D 
ORCID: 0000-0003-4587-2139, Price, Stephen J, Santarius, Thomas, Matys, Tomasz, Zhang, Ting Ting, Finch, Alina, Collins, Peter, Allinson, Kieren et al (show 8 more authors)
(2021)
An Evaluation of the Tolerability and Feasibility of Combining 5-Amino-Levulinic Acid (5-ALA) with BCNU Wafers in the Surgical Management of Primary Glioblastoma.
CANCERS, 13 (13).
3241-.
|
Text
2021_GALA-5 trial.pdf - Published version Download (1MB) | Preview |
Abstract
Background Glioblastoma (GBM) is the commonest primary malignant brain tumour in adults and effective treatment options are limited. Combining local chemotherapy with enhanced surgical resection using 5-aminolevulinic acid (5-ALA) could improve outcomes. Here we assess the safety and feasibility of combining BCNU wafers with 5-ALA-guided surgery. Methods We conducted a multicentre feasibility study of 5-ALA with BCNU wafers followed by standard-of-care chemoradiotherapy (chemoRT) in patients with suspected GBM. Patients judged suitable for radical resection were administered 5-ALA pre-operatively and BCNU wafers at the end resection. Post-operative treatment continued as per routine clinical practice. The primary objective was to establish if combining 5-ALA and BCNU wafers is safe without compromising patients from receiving standard chemoRT. Results Seventy-two patients were recruited, sixty-four (88.9%) received BCNU wafer implants, and fifty-nine (81.9%) patients remained eligible following formal histological diagnosis. Seven (11.9%) eligible patients suffered surgical complications but only two (3.4%) were not able to begin chemoRT, four (6.8%) additional patients did not begin chemoRT within 6 weeks of surgery due to surgical complications. Eleven (18.6%) patients did not begin chemoRT for other reasons (other toxicity (n = 3), death (n = 3), lost to follow-up/withdrew (n = 3), clinical decision (n = 1), poor performance status (n = 1)). Median progression-free survival was 8.7 months (95% CI: 6.4-9.8) and median overall survival was 14.7 months (95% CI: 11.7-16.8). Conclusions Combining BCNU wafers with 5-ALA-guided surgery in newly diagnosed GBM patients is both feasible and tolerable in terms of surgical morbidity and overall toxicity. Any potential therapeutic benefit for the sequential use of 5-ALA and BCNU with chemoRT requires further investigation with improved local delivery technologies.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | glioblastoma, 5-aminolevulinic acid, BCNU wafers, chemoRT, feasibility trial |
| Divisions: | Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 08 Jul 2021 08:21 |
| Last Modified: | 18 Jan 2023 21:36 |
| DOI: | 10.3390/cancers13133241 |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3129129 |
Dimensions
Dimensions
